Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I sold half monday (not yesterday) and bought back low 10, mid 9 and round 8 today...levelling my.nr of shares I had 2 days ago...Who would have thought...
Maybe a big office partner did bite at Maxims?
ANYWAYS, SOMEONE BOUGHT 220K in one order
Was that you Foose? Or you Tagmonster?
Yes Mickeyboy...again we take strides. I wonder if, in your quest to obtain a by you shared at ihub specific amount of shares, you even increased at the 3 and 4 levels of shareprice.... I hope you added too.
PM movement seems to lift the bottom even more, and I wonder if/when their will be testnews too these days.
How much cash is left from last offering? We should be okay for 4 to 5 months I would think...
Thoughts?
Could someone translate this radio interview with CEO Takis from Italian to english pls
podcast/dott-luigi-aurisicchio-genetica-oggi
R u sure about your alias? Sounds more like DTC or Pumpstopper to me....haha
covid-tests-millions-per-day-crispr-biotechnology-advances
Wonder if Adnas will be amongst those test scale up techs the US needs to place bets on too...
Good to hear from you again Mike
Yeah I know... as a relative newby long (since spring 2015) I surely can't recall how often I "bullished to the max all" in vain, back than figuring out already that
BIG manipulation has been part of SP movement all along. I did enjoy iHub fights with Dogturd, Hawainsurfer, Dasmortes types and sketching the massive future potential if the tech in multiple scenarios and markets. Still biggest fan. I own stock ONLY in Adnas.
I did profit a bit from the "Vandalia spike in sept/okt 2015, but got bitten big time rebuying big mostly at the top back than (equivalent of $360 now)
Been avering down the last 4 years, only to be glad about still doing that after the last RS
Still need an SP of 12 to break even though (yes I missed 19 in november).
Hock, wishfull thinking: The times, they are achanging...
Cant/wont say things on his behalf but what he himself mentioned some weeks/months ago in a post is that moved the larger part of his shares (maybe all?) to TYME, with which LinearX/Adnas has a partnership. Thinking he keeps track still.
Yeah Mickyboy... thinking Adnas' emphasis on diagnostics/vaccins will benefit us all step by step.
Glad to still see you hang in here and support (Kinda miss Sharky now)
2 out of 5 positive...
Slunds good to me!
I think evotec-allies-takeda-to-move-into-gene-therapy-r-d is kinda interesting...
Evotec has tested LinearX.
FDA's coronavirus-treatment-acceleration-program-ctap
Wonder if amongst these are Takis/Adnas candidates
Fauci promoting vaccin developers to start producing in advance of tests, just in case, sounds like a hint to perfect storm for a company doing so in the most scalable, pure and costeffective way, perhaps safer too...Thoughts?
How about Haelixa and Clariant?
At the least proof for perceived viability of approach, tech and interest/demand
Kinda missed march 24th news on Takis collaborati g with Pascale Institute of Oncology in Napoli:
24-marzo-2020-takis-e-il-dr-ascierto-insieme-per-combattere-il-covid-19
FDA approvals dont seem to be a slowingdown factor these days...wonder when Adnas testkit would be ready
fda-approves-first-bedside-covid-19-test-by-cepheid
Applied DNA Leverages COVID-19 Vaccine Development and Proprietary Linear DNA Manufacturing Capability to Design
a High Sensitivity Diagnostic Kit for Virus Detection
– Assay under development uses PCR-based detection of viral sequences that code for the Spike protein that is also the target of the Company’s vaccine candidate with Takis Biotech –
- Messenger RNA abundance for Spike in host cells should yield high sensitivity -
STONY BROOK, N.Y., March 19, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and diagnostics, announced today the completion of design of a diagnostic kit for SARS-CoV-2 (the virus that causes the disease COVID-19) being developed for production via the Company’s proprietary PCR-based DNA (LinearDNA™) manufacturing process.
The Company’s announcement follows its statement on March 2, 2020, updating their collaborative progress with Takis Biotech, in Rome, Italy, on a series of LinearDNA™ vaccine candidates against the Spike protein of SARS-CoV-2. Yesterday’s announcement highlighted that the preclinical trials for the jointly developed vaccines have been authorized by the Italian Ministry of Health, and are the first trials in Italy to have reached this stage.
The recently designed novel diagnostic kit focuses on the gene that encodes the surface spike (S) protein, an essential glycoprotein for viral entry into human host cells. Said Dr. James Hayward, president and CEO of Applied DNA: “We aligned 74 variants of the S-gene sequence currently available in the NCBI (National Center for Biotechnology Information) database. This gene is highly conserved, being close to 100% (99.97%) identical across variants; meaning that detection via our diagnostic kit under development should be consistent even against the capacity for this virus to mutate. We believe that we are the first company to engage both in detection and prevention of COVID-19.”
“After in-silico analysis, the assay appears highly accurate and specific for SARS-CoV-2”, said Yuha Sun, Director of Applied Genomics at Applied DNA, and one of the developers of the assay. “Applied DNA plans to conduct in-vitro verification of the in-silico analysis in the coming weeks.”
“Because the Spike protein is very abundant on the virus surface, many copies of the messenger RNA are present per host cell, increasing, we believe, the probable sensitivity of the diagnostic,” said Dr. Mohan Chellani, Director of Diagnostic Regulatory Affairs at Applied DNA.
The Company will undertake the PCR-based manufacture of the positive controls for its proposed kit under its LinearDNA platform and believes that its capacity for such manufacture is unmatched anywhere in the world. “We are approaching partners for the validation of our pending diagnostic with samples from confirmed COVID-19 patients,” continued Dr. Hayward. “We believe our capacity for PCR-based manufacture of linear DNA could be of utility to other diagnostic and vaccine manufacturers.”
Applied DNA makes clear that no commercial partner has been identified to take the developmental diagnostic to market, nor is there any indication that the Company’s diagnostics would be approved by regulators. The assay will use the Applied Biosystems 7500 Fast Dx Real Time PCR instrument, widely deployed in diagnostic labs and hospitals the world over. Once fully validated and ready for shipment, the Company plans to sell the diagnostic kit as “For Research Use only” while awaiting the potential Emergency Use Authorization by FDA, which would empower sales to diagnostic labs.
It's bout time. I wonder how it pops.
Agree with Foose, and tell y'all something else:
Adnas could not only mass produce every global needed dna vaccin in a more safe, pure and costeffective way, it could also prove its origin by tagging the raw materials, capsule, coating, ink, packaging, I bet fluids too. Wonder if the coding dna strings themselves could have noncoding identifying info embedded as well.
"We are not afraid to be tested in court"
All thats missing just yet is a marketcap of 1 bln (once insinuated by Hayward I recall) after a
Sky Rocket ;) to the moon.
Bullish to the max all (it's been a while)
Major moves on minor volume. Sad but true...need a covid19 update.
Nice entries, sad I dont daytrade
pipeline-investigational-therapies-for-covid-19
In case another dna vaccin candidate than Takis/Adnas needs upscaling or purifying or... We might still be in the race rigjt? Thoughts?
Europe, not just Italy, getting nervous now...
My homecountry 18 infected as we speak, 1 family in my hometown (100k citizens). This just tip of iceberg.
Think Adnas/StonyBrook applicated as Testing Lab?
Id like to know in what way LinearX rech is somehow involved in or suitable for RNA tweaked or empowered interventions, in line with this approach:
biontech-car-t-rna-cancer
From Sourcing Journal:
Mike...guess you know already:
Tyme + Eagle
LinearX presenting (along with 400 other companies) next week at Biotech Showcase, sponsored by AstraZenica, Lonza, Johnson&Johnson, Merck and more...
No idea, and no clue as to how I should know...
Haelixa posted this at LI...about tagging technology. Adnas mentioned as well (the way how is...hmmm never mind)
https://www-nanalyze-com.cdn.ampproject.org/c/s/www.nanalyze.com/2019/12/tracking-technologies-supply-chain-transparency/amp/
More are mentioned, many not. References to Adnas competitors in cancerdiagnostics are interesting...So we aim for taking on Sysmex Inostics mainly?
Not ac cvording a recent report on CTC related tech: